scholarly journals Phase III trial of chidamide, a subtype-selective histone deacetylase (HDAC) inhibitor, in combination with exemestane in patients with hormone receptor-positive advanced breast cancer

2018 ◽  
Vol 29 ◽  
pp. viii709 ◽  
Author(s):  
Z. Jiang ◽  
W. Li ◽  
X. Hu ◽  
Q. Zhang ◽  
T. Sun ◽  
...  
Sign in / Sign up

Export Citation Format

Share Document